PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

APPLICATION NUMBER

FILING.RECEIPT DATE

FIRST NAMED APPLICANT

www.uspto.gov
ATTORNEY DOCKET NUMBER

09/834,271

04/12/2001

William Widner

5455.210-US

25907 ROBERT L STARNES 1445 DREW AVE DAVIS, CA 95616

N

CONFIRMATION NO. 4969
FORMALITIES LETTER
OC000000007210564

Date Mailed: 12/19/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")
- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

02/08/2002_CNGUYEN 00000065_501701 09634271-01 EC.105 130.00-CH 003/04/2002 HURRING 03/04/2002 HURRING 03/04/2002 CNGUYEN 00000065_501701 09834271

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY





PATENT SCY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Widner et al.

Confirmation No: 4969

Serial No.: 09/834,271

Group Art Unit: To Be Assigned

Filed: April 12, 2001

Examiner: To Be Assigned

For: Methods For Producing A Polypeptide In A Bacillus Cell

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Response to Notice to File Corrected Application Papers (in duplicate)
- 2. Copy of Notice to File Corrected Application Papers
- Substitute Specification papers 3.
- 4. Sequence Listing
- 5. Sequence Listing Diskette
- Verified Statement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

> **Box Sequence Commissioner for Patents** Washington, DC 20231

on January 9, 2002.

Seleste A. Buriani

(name of person mailing paper)

(signature of person mailing paper)

COPY OF PAPERS ORIGINALLY FILED

Attended Docket No.: 5455.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Widner et al.

Confirmation No: 4969

Serial No.: 09/834,271

Group Art Unit: To Be Assigned

Filed: April 12, 2001

Examiner: To Be Assigned

For: Methods For Producing A Polypeptide In A Bacillus Cell

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to File Corrected Application Papers dated December 19, 2001 (a copy thereof is attached hereto), Applicants submit a Substitute Specification in compliance with 37 C.F.R. 1.52 a paper and computer readable form copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing, where applicable, includes no new matter.

Please charge the required fee, estimated to be \$130.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. Please credit any overpayment to Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 9, 2002

Robert L. Starnes, Reg. No. 41,324

Novozymes Biotech, Inc. 1445 Drew Avenue Davis, CA 95616

(530) 757-8100